Atrys Health (CHIX:ATRYE) DeferredTaxAndRevenue: €0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ATRYE Atrys Health SA CHIX:ATRYE
65 GF Score
Price €6.08
GF Value €7.71
! 5 Warning Signs
View Full Analysis

What is Atrys Health DeferredTaxAndRevenue?

Atrys Health CHIX:ATRYE 65 DeferredTaxAndRevenue is €0.0 Mil as of Dec. 2025. GuruFocus rates CHIX:ATRYE with a GF Score™ of 65/100 and a GF Value™ of €7.71. The stock has 5 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Atrys Health's current deferred tax and revenue for the quarter that ended in Dec. 2025 was €0.0 Mil.

Atrys Health DeferredTaxAndRevenue Related Terms

Atrys Health DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Atrys Health's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrys Health DeferredTaxAndRevenue Chart

Atrys Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Atrys Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:ATRYE
65GF Score
Atrys Health SA CHIX:ATRYE
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of €0.0 Mil mean?
Atrys Health (CHIX:ATRYE) has a DeferredTaxAndRevenue of €0.0 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Atrys Health.
Is Atrys Health's DeferredTaxAndRevenue too high?
Atrys Health's current DeferredTaxAndRevenue is €0.0 Mil. Overall, Atrys Health has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's DeferredTaxAndRevenue compare to VRTX and REGN?
Atrys Health's DeferredTaxAndRevenue of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Atrys Health. Atrys Health's current DeferredTaxAndRevenue is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Atrys Health (CHIX:ATRYE) has a current DeferredTaxAndRevenue of €0.0 Mil. The stock's GF Value™ is €7.71, compared to a current price of €6.08 — trading 21.1% below its estimated fair value. The current DeferredTaxAndRevenue is €0.0 Mil. Atrys Health's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Atrys Health (CHIX:ATRYE), the current DeferredTaxAndRevenue is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (CHIX:ATRYE) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €6.08 is trading 21.1% below its estimated GF Value™ of €7.71.

Key valuation signals for CHIX:ATRYE:

  • DeferredTaxAndRevenue: €0.0 Mil
  • GF Value™: €7.71 vs. price of €6.08 (21.1% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the CHIX:ATRYE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atrys Health Business Description

Other Exchanges ATRY:SpainA2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
65GF Score

Get the complete analysis for CHIX:ATRYE

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.08
Price
€7.71
GF Value